Concepedia

Author

Michael Unterhalt

Ludwig-Maximilians-Universität München

Also Known As

Birgit Braess, M Unterhalt, M. UNTERHALT, M. Unterhalt, MICHAEL UNTERHALT, Michael Unterhalt, Unterhalt, Michael, W. Hiddemann, the German Low-Grade Lymphoma Study Group

258

Publications

10.8K

Citations

48

H-Index

66

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenUniversity of LübeckUniversity Hospital Schleswig-HolsteinUniversity of GöttingenLMU Klinikum
MU

About

Michael Unterhalt is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

29

2K

2

Health Sciences

11

11

324

3

Biochemistry

3

3

55

4

Engineering

1

1

32

5

Allergy

1

1

24

Michael Unterhalt

×

107

Publications

9.9K

Citations

47

H-Index

YearCitations

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Eva Hoster, Martin Dreyling, Wolfram Klapper,

Blood

2007

944

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel,

The Lancet Oncology

2015

608

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

Georg Lenz, Martin Dreyling, Eva Hoster,

Journal of Clinical Oncology

2005

573

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine,

New England Journal of Medicine

2012

511

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling,

Blood

2006

464

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A. Herrmann, Eva Hoster, Thomas Zwingers,

Journal of Clinical Oncology

2008

394

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski,

The Lancet

2016

390

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

Eva Hoster, Andreas Rosenwald, Françoise Berger,

Journal of Clinical Oncology

2016

344

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the <i>European MCL Network</i>

Markus Tiemann, Carsten Schrader, Wolfram Klapper,

British Journal of Haematology

2005

316

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Christiane Pott, Eva Hoster, Marie‐Hélène Delfau‐Larue,

Blood

2009

267

Page 1